lactic acid has been researched along with Hand Dermatosis in 3 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 9.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| "Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated." | 5.14 | Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. ( Berenberg, JL; Christian, D; Delaune, R; Loprinzi, CL; Menon, SP; Pajon, ER; Qin, R; Rowland, KM; Satele, DV; Thomas, S; Wolf, SL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wolf, SL | 1 |
| Qin, R | 1 |
| Menon, SP | 1 |
| Rowland, KM | 1 |
| Thomas, S | 1 |
| Delaune, R | 1 |
| Christian, D | 1 |
| Pajon, ER | 1 |
| Satele, DV | 1 |
| Berenberg, JL | 1 |
| Loprinzi, CL | 1 |
| Shook, BA | 1 |
| Trizna, Z | 1 |
| Auken, G | 1 |
| Gade, M | 1 |
| Pilgaard, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome[NCT00296036] | Phase 3 | 137 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A patient self-reported hand-foot syndrome (HFSD), also known as palmar-plantar erythrodysesthesia, was completed daily while applying the cream. Patients rated skin severity symptoms individually in their hands and in their feet. Definitions of symptoms, which were based on Common Terminology Criteria for Adverse Events (CTCAE) v3.0, were provided to patients. The number of patients reporting moderate to severe symptoms in either hands or feet were tabulated and percentages are reported. (NCT00296036)
Timeframe: First 3 weeks of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Urea/Lactic Acid Cream | 13.6 |
| Placebo Cream | 10.2 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00296036)
Timeframe: Up to 4, 21-day cycles
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Placebo Cream | 18 | 3 |
| Urea/Lactic Acid Cream | 21 | 3 |
2 trials available for lactic acid and Hand Dermatosis
| Article | Year |
|---|---|
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind | 2010 |
[Treatment of warts of the hands and feet with Verucid].
Topics: Clinical Trials as Topic; Copper; Drug Combinations; Foot Dermatoses; Hand Dermatoses; Humans; Lacti | 1975 |
1 other study available for lactic acid and Hand Dermatosis
| Article | Year |
|---|---|
Congenital hyperkeratotic papules in a 15-year-old girl--quiz case.
Topics: Administration, Topical; Adolescent; Biopsy, Needle; Female; Follow-Up Studies; Hand Dermatoses; Hum | 2004 |